AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 78.19 |
|---|---|
| Change | -3.420 4.374% |
| 52 W H/L (in USD) | 89.980/54.110 |
| EBITDA (in USD) | 1163.6M |
| PE Ratio | 30.99 |
| Volume | 4777404 |
| Diluted Eps TTM | 2.02 |
| Total Assets (in USD) | 6339.9M |
|---|---|
| Total Liabilities (in USD) | 3593.9M |
| Revenue TTM (in USD) | 4662M |
| Cash (in USD) | 917.7M |
| Market Cap (in USD) | 24,155.648 M |
| Revenue Per Share TTM | 11.948 |
| Gross Profit TTM (in USD) | 2801.9M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Employees: 11000
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Kevin Ronald Sayer | Exec. Chairman, CEO & Pres | 1958 |
| 2. | Mr. Jereme M. Sylvain | Exec. VP, CFO & Chief Accounting Officer | 1980 |
| 3. | Mr. Jacob Steven Leach | Exec. VP & COO | 1978 |
| 4. | Mr. Paul R. Flynn | Exec. VP of Global Revenue | 1969 |
| 5. | Mr. Sean Christensen | Director of Corp. Affairs & Head of Investor Relations | NA |
| 6. | Mr. Michael Brown | Exec. VP & Chief Legal Officer | 1970 |
| 7. | Mr. Matthew Dolan | Exec. VP of Strategy, Corp. Devel. & Dexcom Labs | 1981 |
| 8. | Ms. Sadie M. Stern | Exec. VP & Chief HR Officer | 1975 |
| 9. | Mr. Andrew K. Balo | Exec. VP of Global Medical Affairs, Access & Evidence | 1948 |
| 10. | Mr. Steven R. Pacelli | Exec. VP & MD of Dexcom Ventures | 1972 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
-2.080 2.280% | 91.32 | 25.970 | 17.241 | 3.570 | 3.200 | 3.805 | 16.753 |
|
SYK
Stryker Corporation |
-5.170 1.646% | 314.72 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
-1.730 2.110% | 82.21 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
-0.620 1.266% | 48.88 | 31.490 | 17.241 | 4.407 | 3.650 | 4.878 | 19.194 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | 1088.4M | 709M | 710.4M | 390.8M | 173.9M |
| Minority Interest | - | - | - | - | - |
| Net Income | 836.3M | 576.2M | 541.5M | 341.2M | 154.7M |
| Selling General Administrative | 1291M | 1091.6M | 1004.6M | 1000.2M | 810.5M |
| Gross Profit | 2801.9M | 2438.2M | 2288.9M | 1883.1M | 1680.5M |
| Reconciled Depreciation | 251.8M | 217.7M | 186M | 155.9M | 102M |
| Ebit | 911.8M | 728M | 730.7M | 391.2M | 175.4M |
| Ebitda | 1163.6M | 945.7M | 916.7M | 416.9M | 277.4M |
| Depreciation And Amortization | 251.8M | 217.7M | 186M | 25.7M | 102M |
| Operating Income | 911.8M | 600M | 597.7M | 391.2M | 175.4M |
| Other Operating Expenses | 3750.2M | 3433M | 3024.6M | 2518.6M | 2182.7M |
| Interest Expense | 18.3M | 19M | 20.3M | 18.6M | 102M |
| Tax Provision | 252.1M | 132.8M | 168.9M | 49.6M | 19.2M |
| Interest Income | 112.7M | 134.2M | 135M | 18M | - |
| Net Interest Income | 94.4M | 115.2M | 114.7M | -18.6M | -100.3M |
| Income Tax Expense | 252.1M | 132.8M | 168.9M | 49.6M | 19.2M |
| Total Revenue | 4662M | 4033M | 3622.3M | 2909.8M | 2448.5M |
| Total Operating Expenses | 1890.1M | 1838.2M | 1691.2M | 1491.9M | 1414.7M |
| Cost Of Revenue | 1860.1M | 1594.8M | 1333.4M | 1026.7M | 768M |
| Total Other Income Expense Net | 176.6M | 109M | 112.7M | -0.4M | -1.5M |
| Net Income From Continuing Ops | 836.3M | 576.2M | 541.5M | 341.2M | 154.7M |
| Net Income Applicable To Common Shares | - | - | - | 341.2M | 154.7M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 6339.9M | 6484.5M | 6264.5M | 5391.7M | 4863.6M |
| Intangible Assets | 70.8M | 103.4M | 134.5M | 173.3M | 42M |
| Other Current Assets | 115.6M | 145.8M | 49.3M | 192.6M | 81.6M |
| Total Liab | 3593.9M | 4381.9M | 4195.9M | 3259.9M | 2612.1M |
| Total Stockholder Equity | 2746M | 2102.6M | 2068.6M | 2131.8M | 2251.5M |
| Other Current Liab | 1768.9M | 1309.5M | 1240.1M | 134.3M | 125.2M |
| Common Stock | 0.4M | 0.4M | 0.4M | 0.4M | 0.1M |
| Capital Stock | 0.4M | 0.4M | 0.4M | 0.4M | 0.1M |
| Retained Earnings | 2433.9M | 1597.6M | 1021.4M | 479.9M | -47.4M |
| Good Will | 24.2M | 22.8M | 25.2M | 25.7M | 26.5M |
| Other Assets | - | - | - | 369.3M | 220.8M |
| Cash | 917.7M | 606.1M | 566.3M | 642.3M | 1052.6M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2142.5M | 2932M | 1556M | 1839.3M | 720.8M |
| Current Deferred Revenue | 7.7M | 8M | 18.4M | 10.1M | 2.1M |
| Net Debt | 472M | 1981.3M | 2027.7M | 1443.1M | 769.2M |
| Short Term Debt | 21.6M | 1226.9M | 21.1M | 793.1M | 20.5M |
| Short Long Term Debt | - | 1204.4M | - | 772.6M | - |
| Short Long Term Debt Total | 1389.7M | 2587.4M | 2594M | 2085.4M | 1821.8M |
| Other Stockholder Equity | 196.7M | 512.6M | 1063.5M | 1663.1M | 2298.3M |
| Property Plant Equipment | - | - | - | 1135.6M | 889.9M |
| Total Current Assets | 4033.3M | 4301.4M | 4425.9M | 3668.8M | 3684.4M |
| Long Term Investments | 218M | 119.3M | 38.5M | - | - |
| Short Term Investments | 1081M | 1973.3M | 2157.8M | 1813.9M | 1678.6M |
| Net Receivables | 1289.9M | 1033.6M | 987.5M | 713.3M | 514.3M |
| Long Term Debt | 1240.9M | 1237M | 2434.2M | 1197.7M | 1702.7M |
| Inventory | 629.1M | 542.6M | 559.6M | 306.7M | 357.3M |
| Accounts Payable | 344.3M | 345.3M | 276.4M | 901.8M | 573M |
| Accumulated Other Comprehensive Income | 115M | -8M | -16.7M | -11.6M | 0.5M |
| Non Currrent Assets Other | 60.7M | 53.7M | 36.5M | 47.1M | 2M |
| Non Current Assets Total | 2306.6M | 2183.1M | 1838.6M | 1722.9M | 1179.2M |
| Capital Lease Obligations | 148.8M | 146M | 159.8M | 174.7M | 119.1M |
| Long Term Debt Total | - | - | - | 1197.7M | 1702.7M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 898.9M | -207.5M | -1116.2M | -138.5M | 193.2M |
| Total Cashflows From Investing Activities | 536M | -207.5M | - | -521.5M | -216.1M |
| Total Cash From Financing Activities | -1686.4M | -734.8M | -318.6M | -552.5M | 10.4M |
| Net Income | 836.3M | 576.2M | 541.5M | 341.2M | 154.7M |
| Change In Cash | 311.8M | 39.8M | -75.8M | -410.3M | 235.4M |
| Begin Period Cash Flow | 607.3M | 567.5M | 643.3M | 1053.6M | 818.2M |
| End Period Cash Flow | 919.1M | 607.3M | 567.5M | 643.3M | 1053.6M |
| Total Cash From Operating Activities | 1440.7M | 989.5M | 748.5M | 669.5M | 442.5M |
| Depreciation | 251.8M | 217.7M | 186M | 155.9M | 102M |
| Other Cashflows From Investing Activities | 0.6M | -15.5M | - | -18.2M | -20.1M |
| Dividends Paid | - | - | 1230.6M | - | - |
| Change To Inventory | -63.7M | 12.4M | -252.6M | 49.3M | -112.2M |
| Sale Purchase Of Stock | -500M | -750M | -688.7M | -557.7M | 20.3M |
| Other Cashflows From Financing Activities | -7M | -13M | -99.8M | -17.3M | -9.9M |
| Capital Expenditures | 363.5M | 358.8M | 236.6M | 364.8M | 389.2M |
| Change In Working Capital | 103.4M | 108.8M | 3.2M | 27.7M | -132M |
| Other Non Cash Items | -92.6M | -39.8M | -78M | 39.8M | 209.3M |
| Free Cash Flow | 1077.2M | 630.7M | 511.9M | 304.7M | 53.3M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 12225879 |
| 2. | State Street® SPDR® S&P 500® ETF | 2 months ago | 4443700 |
| 3. | UBS: Global Equity | 5 months ago | 4174754 |
| 4. | AllianceBernstein US L/C Growth Eqty MF | 3 months ago | 2983610 |
| 5. | Vanguard Mid-Cap Growth ETF | 2 months ago | 2927322 |
| 6. | BlackRock Mid-Cap Growth Equity Instl | 3 months ago | 2892286 |
| 7. | State Street®HlthCrSelSectSPDR®ETF | 2 months ago | 2812955 |
| 8. | iShares Russell Mid-Cap Growth ETF | 2 months ago | 2619257 |
| 9. | Invesco S&P 500® Equal Weight ETF | 2 months ago | 2618442 |
| 10. | Vanguard Institutional Index I | 2 months ago | 2170471 |
| 11. | Xtrackers MSCI World Swap ETF 1C | 5 months ago | 2145773 |
| 12. | State St S&P 500® Indx SL Cl III | 2 months ago | 2054485 |
| 13. | JPMorgan Mid Cap Growth I | 3 months ago | 1793200 |
| 14. | JPM US Mid Cap Growth-Composite | 2 months ago | 1783253 |
| 15. | Vanguard 500 Index Investor | 2 months ago | 9799374 |
| 16. | Vanguard Mid Cap Index Institutional | 2 months ago | 8314081 |
| 17. | Invesco QQQ Trust | 2 months ago | 8077454 |
| 18. | Fidelity 500 Index | 3 months ago | 4963444 |
| 19. | iShares Core S&P 500 ETF | 2 months ago | 4946613 |
| 20. | Vanguard Growth Index Investor | 2 months ago | 4852240 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 5 months ago | 49074378 |
| 2. | BlackRock Inc | 8 months ago | 38821843 |
| 3. | State Street Corp | 8 months ago | 16855113 |
| 4. | Baillie Gifford & Co Limited. | 5 months ago | 15552587 |
| 5. | JPMorgan Chase & Co | 8 months ago | 12427514 |
| 6. | Geode Capital Management, LLC | 5 months ago | 11006183 |
| 7. | UBS Asset Mgmt Americas Inc | 8 months ago | 7482531 |
| 8. | NORGES BANK | 5 months ago | 7282743 |
| 9. | Jennison Associates LLC | 5 months ago | 5789944 |
| 10. | Nuveen, LLC | 5 months ago | 4632271 |
| 11. | Amvescap Plc. | 8 months ago | 4629139 |
| 12. | Morgan Stanley - Brokerage Accounts | 8 months ago | 4352808 |
| 13. | Deutsche Bank AG | 5 months ago | 4329213 |
| 14. | Bank of America Corp | 8 months ago | 4327022 |
| 15. | D. E. Shaw & Co LP | 5 months ago | 3938568 |
| 16. | Northern Trust Corp | 8 months ago | 3721544 |
| 17. | Federated Hermes Inc | 8 months ago | 3420262 |
| 18. | Royal Bank of Canada | 8 months ago | 3162653 |
| 19. | Atlantic Trust Group, LLC | 5 months ago | 3128114 |
| 20. | Amundi | 5 months ago | 4917921 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...